Thrombocytopenia is the most common haemostatic disorder in patients admitted to Intensive Care Units (ICUs). The mechanisms contributing to a decrease in the platelet count in critically ill patients are multifactorial, among which sepsis and trauma are the most frequent. A differential diagnosis of profound thrombocytopenia is crucial for effective treatment. A low platelet count is a strong independent predictor of morbidity and mortality because it is associated with life-threatening bleeding or thrombosis. This article aims to outline the definition and pathophysiology of thrombocytopenia and present a three-step algorithm of the clinical management of this haemostatic disorder.
A low platelet count or thrombocytopenia (TP) is the most common haemostatic disorder in patients hospitalised in intensive care units (ICUs). TP is defined as a platelet (PLT) count of < 150 G L -1 and is observed in almost half of patients admitted to the ICU. During hospitalisation, this percentage increases to as much as to 66% [1] . A platelet count of < 50 G L -1 is considered severe.
Given a large number of factors responsible for the development of TP and their concomitance, the diagnosis of TP poses a challenge in everyday clinical practice. The knowledge of mechanisms responsible for reduced PLT counts has contributed to the use directed therapy, which can lead to the increased safety of patients in immediate life-threatening conditions. The simplified acute physiology score (SAPS, multiple organ dysfunction syndrome (MODS) and acute physiology and chronic health evaluation (APACHE) have demonstrated a higher risk of death among patients with thrombocytopenia hospitalised in ICUs, as compared with individuals with normal PLT counts [2, 3] .
PlAtelets And hAeMostAsis
Platelets are the major element of the cellular model of haemostasis. Together with the vascular endothelial elements, they are responsible for primary haemostasis, whose final stage is the formation of a platelet plug. The process of formation of a platelet thrombus clot is composed of three stages: activation, adhesion and aggregation [4] . The activation of adenosine diphosphate (ADP)-implicated PLT leads to changes in their shape and the formation of pseudopods adhering to collagen fibres on the surface of the damaged endothelium. Moreover, the presence of von Willebrand factor is indispensible for the proper course of the above processes, which acts as a bridge connecting to the subendothelial matrix [5] . The final stage of primary haemostasis is aggregation, during which the platelet plug increases in size due to the earlier activated platelets. This process is supplemented with secondary haemostasis dependent on serum clotting factors, which results in the formation of a stable thrombus consisting of PLT covered with a network of fibrin fibres [6] . This process is impaired by TP, in particular, profoundly increased TP.
MechAnisMs of thRoMbocytoPeniA
The aetiology of TP in the ICU is most often complex. A diagnosis of TP should be implemented when the PLT count has decreased below 100 G L -1 or by more than 30% of the baseline value [1] .
Considering its aetiology, TP is divided into central (associated with reduced production of PLT in the bone marrow) and peripheral (connected with the "extra-marrow" issue, i.e. improper distribution or enhanced destruction). Appropriate classification is essential for taking correct therapeutic decisions, including platelet concentrate (PC) transfusions.
Greinacher et al. [7] have distinguished the main mechanisms of TP observed in patients under life-threatening conditions, which include: -pseudothrombocytopenia, -haemodilution-induced thrombocytopenia, -excessive PLT usage, -excessive destruction of sequestration of PLT (including immunologically based), -reduced production of PLT in the bone marrow.
The detailed divisions and aetiology are presented in Table 1 .
diAgnosis of thRoMbocytoPeniA in the icu
The most important causes of low PLT count in critically ill patients include TP: -pseudo-TP, -secondary haemorrhage, haemodilution-associated TP, -during sepsis, DIC, -drug-induced, particularly heparin-induced TP.
The causes listed above do not include the specificity of haematological-oncological units in which bone marrow failure is the main aetiology of TP. During differential diagnosis, TP as an element of systemic syndromes, e.g. systemic lupus or AIDS, should be considered.
The stages of TP diagnosis are presented below. They may facilitate the determination of causes and the implementation of suitable management in this group of patients.
stAge 1: exclusion of PseudothRoMbocytoPeniA
Pseudothrombocytopenia is a phenomenon which is a laboratory artefact. A low PLT count in blood tests results from the presence of auto-antibodies dependent on EDTA present in the test-tube. These antibodies (most commonly cold antibodies) cause agglutination of PLT leading to a decrease in their number due to an incorrect addition by automated haematology analysers. The incidence of this phenomenon, which is not of clinical relevance, is estimated at 0.1-2% [6] . Low PLT counts (sometimes below 20 G L -1 ) Patients at particular risk of pseudothrombocytopenia are those subjected to procedures in the haemodynamic laboratory, receiving GPIIbIIIa-inhibiting drugs (abciximab, tirofiban and eptifibatide). This receptor is believed to be the place of absorption of antiplatelet antibodies while its antigenic determinant is revealed in the presence of EDTA [8] . A higher percentage of pseudothrombocytopenia has been demonstrated in this group of patients, as well as when the citrate anticoagulant was used. Therefore, in such cases both alternative anticoagulants -citrate and heparin -are applied.
Considering the above problem, it should be remembered that true TP in patients treated with GPIIbIIIa inhibitors can substantially increase the risk of haemorrhagic complications while unjustified discontinuation of antiplatelet therapy in patients with pseudothrombocytopenia can lead to blood clotting in a stent [7] . Therefore, a microscopic blood smear can be essential for the final diagnosis. This smear enables one to assess PLT morphology (their structure and size) providing information about the presence of platelet aggregates [6] .
stAge 2: deteRMinAtion of the Most PRobAble cAuse of thRoMbocytoPeniA
The quick and proper differentiation of the causes of TP in critically ill patients is pivotal to the implementation of most effective treatment. The PLT count should return to the baseline value after 3-4 days, provided there are no factors impairing the reconstruction of the thrombocyte population after sudden PLT loss (e.g. surgery). A slow decrease in the PLT count over 5-7 days suggests their excessive usage or decreased production. Sudden and marked decreases in PLT counts (1-2 days) are most likely to indicate the immunological cause of TP (post-transfusion or post-drug reactions).
According to Thiele et al. [3] , the most common causes of TP in ICUs are sepsis, massive trauma with haemodilution and DIC [9] . The other common causes include liver diseases, hypersplenism and drug-induced thrombocytopenia.
sePsis And disseMinAted intRAvAsculAR coAgulAtion
The most frequent cause of true TP in ICU patients is sepsis [1]. According to Vanderschueren et al. [3] , sepsis accounts for 48% of TP cases in ICUs. Generalised infection leads to TP through the decreased production of PLT, as well as enhanced destruction. In sepsis and septic shock with multiple organ failure, slow, progressive and most commonly severe TP is observed (20-50 G L -1 ). Such a course indicates the non-immunological nature of TP [2] .
The prerequisite of TP treatment is the effective management of sepsis. In many cases, the management involves antibiotic therapy plus surgical intervention to remove the infected tissues. In such cases, an increased risk of bleeding should be taken into account.
Prophylactic platelet concentrate (PC) transfusion is recommended in sepsis at a PLT count of < 10 G L -1 and a lack of active bleeding or a count of < 30 G L -1 when increased risk of bleeding is found. A PLT count of > 50 G L -1 is an indication for transfusion in active bleedings and when invasive procedures have to be performed. However, this is a recommendation base on weak and low-quality evidence [10, 11] .
The difficulty in determining strong recommendations concerning PC transfusions results from the complex role of PLT in sepsis. PLT usage is a natural element of the host response to infection depending on its severity and intensity. Platelets protect and ensure endothelial continuity, playing an important role in limiting infection and haemorrhagic complications [12] . On the other hand, animal studies have demonstrated possible PLT involvement in the development of infection and coagulopathy [13, 14] . Nevertheless, these observations cannot be directly extrapolated to clinical studies in humans.
TP in sepsis is particularly often accompanied by DIC [1], i.e. generalised, uncontrolled activation of the coagulation system resulting in the production of substantial amounts of fibrin. As a result, the blood flow in microcirculation is blocked, contributing to the development of multiple organ failure [15] .
The probability of DIC can be assessed based on the scale recommended by the International Society on Thrombosis and Haemostasis (ISTH) ( Table 2 ).
An important element of DIC treatment is the management of the underlying disease. If the cause is placental detachment in a pregnant woman, the delivery leads to DIC subsidence. In neoplastic diseases, chemotherapy and radiation therapy have been found to be effective [5] . In a paper from 2014, Wada et al. [17] analysed the recommendations of several scientific societies regarding the management of DIC. The authors have concluded that PC transfusions are grounded in patients actively bleeding and with a PLT count of ≤ 50 G L -1 ; in cases without bleeding and a PLT count of 10-20 G L -1 , while transfusions are particularly recommended in those after chemotherapy. Windyga et al. [18] have emphasised that despite the commonly held opinion, transfusions of PC in patients with acute DIC is not an error (adding "fuel to the fire") but should be confined to selected situations, e.g. preparation for emergent surgery. The use of anticoagulants for DIC treatment has given rise to many controversies. Although it seems logical to inhibit the process of disseminated clotting, heparin is likely to intensify the risk of bleeding in this group of patients. Therefore, it should be remembered that one of the main contraindications for the use of anticoagulation in DIC is severe thrombocytopenia accompanied by active bleeding [5] .
hAeModilution And usAge-induced coAguloPAthy
In patients admitted to ICU after surgery associated with substantial intraoperative blood loss, TP should subside within several hours. Besides the loss of PLT, a common cause of TP is haemodilution resulting from transfusions of large amounts of infusion fluids. Therefore, perioperative restrictive fluid therapy has been found to be beneficial [19, 20] . The prospective analysis of 1,490 patients in the RELIEF study, however, has not demonstrated its positive effects on survival in the group undergoing restrictive fluid therapy and has indicated an increased risk of postoperative renal failure [21] .
TP can also be an element of usage-induced coagulopathy due to massive blood loss resulting from post-traumatic haemorrhage. The European guidelines of 2016 demonstrated that the PLT count on admission to hospital played a key role in the assessment of the severity of trauma sustained and correlated with mortality. In cases of secondary TP, the transfusion of 4-8 fused units or 1 therapeutic unit (apheresis) of PC is usually effective to restore platelet haemostasis, increasing the PLT count by 30-50 G L -1 [22] .
Postoperative TP lasting longer than 3-4 days should be an indication to broaden the diagnostic procedures and determine the causes of inability to restore the baseline PLT count.
liveR diseAses
In patients with end-stage liver failure significant haemostatic disturbances are observed, resulting from the production of many clotting factors in the liver, as well as elements of the fibrinolysis system [5] . Additionally, a deficiency of thrombopoietin synthesised in the liver is responsible for impaired production of PLT. According to some authors, the use of thrombopoietin receptor antagonists can contribute to reduced requirements for allogenic platelet preparations. The above method is not effective in urgent cases as the thrombopoietin effect is achieved after several days of treatment [23] .
Splenomegaly associated with reverse hypertension and enhanced blood flow through the spleen is responsible for the excessive destruction of PLT in liver diseases [24] . Splenomegaly can lead to "trapping" of over 90% of the total platelet mass. The therapeutic management is based on the treatment of liver diseases responsible for reverse hypertension. Moreover, splenectomy or splenic artery embolisation immediately restores proper PLT counts, unless there are secondary causes [5] .
It should be remembered that abnormal laboratory results (reduced PLT count, hypofibrinogenemia and prolonged clotting time) cannot be considered the only indication for transfusion of blood preparations. In patients with hepatic cirrhosis, an elevated risk of bleeding is balanced by lower concentrations of clotting-inhibiting factors, which leads to a rebalanced haemostasis (new and lower) [25] . In this group of patients, the use of global haemostasis tests (thromboelastometry, thromboelastography) during surgical procedures enables a more individualised assessment of the bleeding risk and haemostatic potential, which consequently leads to reduced requirements for transfusions of blood components [26, 27] .
dRug-induced thRoMbocytoPeniA
Many drugs used in ICUs reduce PLT counts. The occurrence of severe symptomatic TP can enforce changes in pharmacotherapy (e.g. broad-spectrum antibiotic therapy)
The mechanism of drug-induced TP can be immunological (drug-induced immune thrombocytopenia-DITP) and non-immunological (drug-induced non-immune thrombocytopenia-DTP) [28] . DTP leading to TP in the mechanism of bone marrow suppression is clearly more common. The drugs responsible for DTP mainly include chemotherapeu-tics. Some antibiotics, such as linezolid, daptomycin, ganciclovir, also reduce the production of PLT [29] .
DITP is underlined by the enhanced destruction of PLT by antibodies formed due to exposure to drugs. TP, often at a count of < 20 G L -1 , develops within 5-10 days after drug exposure, or within several hours if the drug has been taken in the past [30] . The drugs used in ICUs that can be responsible for TP are presented in Table 3 .
The immunological cause of TP (often suspected although rarely confirmed) is heparin-induced thrombocytopenia (HIT), which concerns mostly cardiac surgery patients undergoing procedures with extracorporeal circulation (up to 10% in this group) [31] .
The 4T scale is recommended for the diagnosis of HIT, which includes 4 parameters. The 4T scale, along with some other issues regarding HIT, was comprehensively described in the paper published in the same journal in 2015 [32] . A score of 0-3 indicates a low probability of HIT, with 4-5 and 6-8 representing medium and high probabilities, respectively [33] .
It is extremely important to identify patients at risk of heparin-induced thrombocytopenia with thrombosis (HITT) due to a high risk of thrombotic complications.
stAge 3:exclusion of RARe cAuses of thRoMbocytoPeniA
In cases where reduced PLT counts cannot be explained by the earlier-described clinical conditions, rarer causes should be considered.
Given the specificity of diagnostic management, thrombohaemorrhagic syndromes are particularly relevant. They include thrombotic microangiopathies (TMAs), among which thrombotic thrombocytopenic purpura (TTP) and haemolytic uremic syndrome (HUS) are worth highlighting. The above syndromes are characterised by a triad of symptoms, namely: TP; non-immunological haemolytic anaemia; and ischaemic damage to the organs associated with rich-platelet emboli in the microcirculation. In TTP, sudden haemolytic anaemia is accompanied by symptoms of brain ischaemia, while in HUS, these are symptoms connected with renal failure [18] . TMA is confirmed by a peripheral blood smear demonstrating the presence of numerous schistocytes erythrocytes damaged during "squeezing" through fine blood vessels filled with clots [5] . Their presence indirectly provides evidence for clots in the microcirculation. In TMA, the schistocyte count is high while in DIC the percentage does not exceed 10% of all erythrocytes [18] .
Another element of TMA diagnosis is the assessment of a deficiency of disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) -proteases cleaving von Willebrand factor (vWF). In cases of its deficiency, ultra-large vWF (ULvWF) multimers are produced from PLT, leading to the formation of thrombi blocking the blood vessel flow. The activity of ADAMTS13 below 5% speaks in favour of a TTP diagnosis. On the other hand, in HUS, the activity of ADAMTS13 is > 5-10%, and the disturbances result from a complement deficiency [18] . Specific therapeutic management involves prompt plasmapheresis (therapeutic plasma exchange). The procedures should be repeated every day for about 5-7 days until the PLT count has been stabilised. If plasmapheresis is infeasible, fresh frozen plasma should be transfused (20 mL kg -1 ) [34] including autoimmune diseases. The aim of the present study was to analyse the incidence of plasmapheresisrelated complications in patients treated in the intensive care unit (ICU. Due to a high risk of venous thromboembolic disease in the course of TTP, antithrombotic prophylaxis is recommended in cases of an increased PLT count of > 50 × 10 9 L -1 . Therefore, the transfusion of PC in patients with TTP should be considered only in cases of life-threatening haemorrhaging [5] .
Considering severe clinical consequences, special attention should be paid to TP in pregnant women. In 70% of cases, TP in pregnancy is mild and asymptomatic. Severe TP should incline one to search for such causes as preeclampsia, HELLP syndrome (in these syndromes, as in HUS, ADAMTS13 is above 5-10% of norm) or TTP [35] .
Acquired TTP in a pregnant woman, related to immunological conditions such as ADAMTS13 deficiency deficit is an indication for immediate plasma exchange with possible glucocorticosteroid therapy [5] . FFP supplies the lacking protease while plasmapheresis removes ADAMTS13 anti-antibodies, ULvWF and cytokines [36] . The management of choice is delivery once the foetus is capable of self-reliant life [5] . Table 4 presents the summary of the diagnosis and treatment of the types of TP characteristic of ICU patients. Patients hospitalised in ICUs are characterised by complex clotting disturbances. The relevant risk factors of thromboembolic complications in this group are an indication for antithrombotic prophylaxis. Thus, the more intensive the TP, the higher the risk of haemorrhagic complications. However, the occurrence of TP, without the consideration of the clinical situation, cannot be the only indication for discontinuing antithrombotic therapy. It should be remembered that even severe TP can be accompanied by an increased risk of thrombotic complications, as in DIC or HITT.
Antithrombotic prophylaxis in the ICU using unfractionated heparin (UFH) or low-molecular-weight heparin (LOWH) is recommended when the PLT count is > 30 G L -1 . An exception are patients whose therapeutic management should be individualised due to a high risk of bleedings [1]. Greinacher et al. [7] have suggested that in patients requiring therapeutic doses of antithrombotic drugs (e.g. with symptomatic thromboembolic diseases) with the PLT count < 50 G L -1 , the dose of anticoagulants should be halved; at a PLT count of < 30 G L -1 , a prophylactic dose ought to be used, while in cases of < 20 G L -1 , antithrombotic treatment should be discontinued. In those treated with antiplatelet drugs at risk of haemorrhaging, the drugs should be discontinued when TP is < 50 G L -1 [1]and therapeutic approaches differ according to these different causes. However, no guideline exists regarding optimum practices for these situations in critically ill patients. We present recommendations for the management of thrombocytopenia in intensive care unit, excluding pregnancy, developed by an expert group of the French-Language Society of Intensive Care (Société de Réanimation de Langue Française [SRLF]).
A separate issue is PC transfusion. Since TP is common in critically ill patients, not every case of TP requires management while its diagnosis should not be the only factor deciding about PC transfusions. The clinical picture is of key importance, especially the co-existence of an active haemorrhage. Its severity can be assessed using the 4-point scale designed by the World Health Organization (WHO). PC transfusion is justified by severe TP (< 50 G L -1 ) accompanied by haemorrhage ≥ 2 [7] hemodilution, increased consumption, decreased production, increased sequestration, and immune-mediated destruction of platelets.
The risk of spontaneous haemorrhage increases when the PLT count is lower than 10-20 G L -1 [6] . Based on indications for PC transfusions, the aetiology of TP should also be considered. The most effective aetiology will be that underlain by the reduced formation of PLT in the bone marrow (central thrombocytopenia), as opposed to clinical situations, such as TTP, HUS or HIT, when PC transfusions are not recommended due to possible thromboembolic complications [1] . Prophylactic PC transfusions in TP patients awaiting invasive procedures (e.g. central venous line or tracheotomy) are the most widely disputed. Table 6 lists the recommendation regarding the safety of invasive procedures in TP patients. The primary haemostatic disturbances can be induced not only by TP but also thrombocytopathy, which may result from the use of antiplatelet drugs, among other things. This is particularly important for the differentiation of haemorrhage causes in patients when taking drug-related history is infeasible. Authors describing the mechanisms of posttraumatic coagulopathy have emphasised the relevant role of functional PLT disturbances, in many cases preceding quantitative changes [22] . Their dysfunction can also result from the changes associated with chronic renal failure [40] . In such cases, despopressin can be somewhat beneficial, increasing the plasma concentration of VIII factor and vWF [41] respectively.
Therefore, a functional assessment of PLT is increasingly widely recommended in ICU patients, using global haemostasis tests (ROTEM Platelet), evaluation of occlusion time (PFA200), aggregation (Multiplate) [26, 42] . Their use enables one to determine the cause of clotting disorders in TP patients with normal PLT counts in the clinical setting suMMARy Care of ICU patients with TP requires extensive knowledge and inquisitive diagnosis. The key element of proper diagnosis and implementation of directed treatment is detailed history-taking and the analysis of medical records, especially concerning acute and chronic diseases and drugs taken. Even substantially lowered PLT counts, particularly as an isolated pathology, should always be verified. Prior to the implementation of therapy, especially associated Table 6 . Minimum PLT values required for safe procedures [37] [38] [39] with modification of the treatment already being applied, pseudothrombocytopenia should be excluded by simultaneous evaluation of testing results of the blood collected for EDTA -an alternative anticoagulant. After exclusion, the trend of the PLT count decrease should be analysed during following blood tests. The determination of the baseline PLT count before the development of the disease that led to ICU hospitalisation is of greatest importance. Those patients with TP may include individuals with chronic thrombocytopenia, unrelated to the present life-threatening condition. Additional analysis of the time and dynamics of TP occurrence and subsidence may limit the number of its potential causes by elimination, thus minimising the risk of wrong diagnosis and therapeutic management.
